Senseonics Holdings, Inc. Common Stock

Day range

$7.47 – $7.76

Open

$7.56

Prev close

$7.51

Volume

276.35K

Market cap

$397.08M

Shares out

41.8M

P/E

—

P/S

8.18

P/B

4.40

P/FCF

—

ROE

-121.1%

ROA

-61.9%

Debt/Equity

0.62

Div yield

0.00%

As of Oct 23, 2026

• Asset purchase or saleJun 8, 2026

  the Purchaser Parties agreed to acquire Seller's and as applicable, Seller Parties', right, title and interest in and to certain assets related to Seller's commercial Eversense CGM activities in Italy, Germany, Spain and Sweden (such assets, the 'European Purchased Assets') and, in connection therewith, the assumption of certain liabilities and obligations associated with the European Purchased Assets

• Annual meeting resultsMay 20, 2026

  At the 2026 Annual Meeting of Stockholders held on May 20, 2026, the stockholders of the Company considered six proposals. Of the 41,795,466 shares outstanding as of the record date, 23,650,239 shares, or 56.59%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

• Credit facilityMay 4, 2026

  On May 1, 2026, Senseonics Holdings, Inc. entered into a Second Amendment to Loan and Security Agreement with the several financial institutions or entities party thereto and Hercules Capital, Inc., which further amends the Company's existing Loan and Security Agreement, dated as of September 8, 2023. Pursuant to the Amended Loan Agreement, the Lenders have agreed to make available to Senseonics up to $140.0 million in senior secured term loans.

• Public offeringMay 1, 2026

  the Company agreed to issue and sell an aggregate of 8,000,000 shares of the Company's common stock, par value $0.001 per share and 8,000,000 pre-funded warrants, each representing the right to purchase one share of Common Stock at an exercise price of $0.001 at a price to the public of $5.00 per share (or $4.999 per Pre-Funded Warrant). The net proceeds to the Company from the offering are expected to be approximately $74,745,000, after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, or $86,025,000 if the Underwriters exercise in full their option to purchase 2,400,000 additional shares.

• Asset purchase or saleMar 12, 2026

  the Purchaser Parties acquired Seller's and as applicable, Seller's affiliates', right, title and interest in and to certain assets related to Seller's marketing, selling and distribution of the Eversense® product in the United States effective January 1, 2026.

Days to cover

6.3

Short interest

5.37M

Avg volume

847.52K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World’s First CGM System with No On-body Component
  positiveGlobeNewswire Inc.· Oct 26, 2026
• Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal
  neutralZacks Investment Research· Sep 29, 2026
• Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market Insights
  positiveGlobeNewswire Inc.· Jul 14, 2026
• Senseonics Announces Pricing of $80 Million Public Offering of Common Stock and Pre-Funded Warrants
  positiveGlobeNewswire Inc.· Apr 30, 2026
• Middle East and Africa Continuous Glucose Monitoring Market Forecast and Company Analysis Report 2026-2034 Featuring Dexcom, Medtronic, Senseonics, Abbott Diabetes Care, and GlySens
  positiveGlobeNewswire Inc.· Apr 29, 2026